-
SABCS 2024 | Dr. Biyun Wang: Pharmacokinetics and Preliminary Efficacy of GQ1001 Combined with Pyrotinib in HER2+ MBC Patients Previously Treated
The treatment of HER2-positive breast cancer remains a focal point in clinical research. At the 2024 San Antonio Breast Cancer Symposium (SABCS), a phase 1b study led by Dr. Biyun Wang from Fudan University Shanghai Cancer Center presented promising results (Abstract No. P5-05-02). This study explored the pharmacokinetics and preliminary efficacy of a novel HER2…
-
Dr. Nanlin Li: Efficacy and Safety of Envafolimab Combined with Pyrotinib and Nab-Paclitaxel in Neoadjuvant Therapy for HER2-Positive Breast Cancer
At the 2024 San Antonio Breast Cancer Symposium (SABCS), one of the world’s most prestigious events in breast cancer research, Chinese scholars once again demonstrated their exceptional expertise and innovative spirit in the field of breast cancer treatment. A groundbreaking study led by Dr. Nanlin Li and his team from Xijing Hospital of the Air…
-
Dr. Yunjian Liu: The Emerging Value of ctDNA Monitoring in Neoadjuvant Therapy for Breast Cancer—Predicting Treatment Response and Recurrence Risk
From December 10 to 13, 2024, the 47th San Antonio Breast Cancer Symposium (SABCS) took place in San Antonio, USA. As one of the largest and most prestigious scientific gatherings in the field of breast cancer research, SABCS showcased the latest findings, clinical practices, treatment advancements, and technological innovations from the past year.Among the many…
-
Dr. Tao Sun: Efficacy and Safety of the Triple Combination of Penpulimab, Anlotinib, and Nab-Paclitaxel as First-Line Therapy for Advanced TNBC
Among breast cancer subtypes, triple-negative breast cancer (TNBC) has long been a clinical challenge due to its high malignancy and poor prognosis. Traditional therapies for advanced TNBC often yield suboptimal results, but the rise of immunotherapy has brought new hope to patients.
-
AASLD Expert Interview丨Dr. Lungen Lu Shares New Advances in MASLD Research
Hepatology Digest: What studies did you find most noteworthy at this year’s conference? Could you briefly introduce these studies and their clinical significance? Dr. Lungen Lu: It’s an honor to…
-
AASLD 2024 | Dr. Hong Tang’s Team Advances HBV, MASLD, Liver Fibrosis, HCC, and ACLF Research
Part 1: Hepatitis B Imatinib Promotes HBV Reactivation via Oxidative Stress-Induced Incomplete Autophagy (Poster No. 1242) Imatinib, a landmark drug in molecular targeted cancer therapy, carries a high risk of…
-
Unveiling Highlights from the CAHON Winter Symposium 2024!
On December 6, CAHON brought together a distinguished group of hematology and oncology experts at The University Club Atop Symphony Tower in San Diego, CA. The symposium was a celebration of collaboration, innovation, and mentorship.
-
SABCS 2024 | Prof. Yongmei Yin Connects with Prof. Qiang Liu: Key Findings from the Conference’s Final Day on Immunotherapy Advances
The 47th San Antonio Breast Cancer Symposium (SABCS), held from December 10–13, 2024, in San Antonio, USA, showcased the latest research, clinical practices, and technological innovations in breast cancer. In this special installment of the “Highlights Series,” hosted by Prof. Yongmei Yin of Jiangsu Provincial People’s Hospital, Prof. Qiang Liu from the Sun Yat-sen Memorial…
Connecting Medical Expertise through Media